MedPath

Repetitive Transcranial Stimulation (rTMS) for Resistant Depression in Adolescents

Phase 1
Conditions
Adolescent Depression
Registration Number
NCT01170520
Lead Sponsor
Shalvata Mental Health Center
Brief Summary

The investigators hypothesis that repetitive transcranial Stimulation (rTMS) is a safe and effective add-on therapy for resistent depression in adolescent patients.

A group of adolescents suffering from non psychotic major depression that was resistant to at least 2 drug trials and a trail of psychotherapy will be recruited. After an informed consent procedure for both parents and patients, patients will go through a clinical and cognitive evaluation. They will receive a protocol of 4 weeks (20 work days) of rTMS using the figure of 8 magstim coil at 100% threshold, 42 trains of 4 seconds each, intertrain interval of 30 sec to the LDPC, 1680 pulses per day. Then they will be reevaluated.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
24
Inclusion Criteria
  • Age 15-18 years old
  • Right hand dominant
  • Suffering from major depression
  • CDRS > 60
  • At least 3 months of current depressive episode
  • Failed 2 drug trials (or 3 drug trials if trial terminated prematurely due to side effects) and at least 1 course of psychotherapy
  • No contraindication for rtms (safety questionnaire)
  • No change in pharmacotherapy in the last month
Exclusion Criteria
  • Schizophrenia or psychotic symptoms
  • Hypertension
  • Epilepsy
  • History of major head trauma
  • Metal implements in the head
  • History of neurosurgery
  • History of severe head migraine
  • History of hearing loss or sp cochlear transplantation
  • Pregnancy
  • Current drug abuse
  • Unstable medical condition
  • History of manic episode
  • Current treatment with lithium or tricyclic or tetracyclic antidepressants

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Child Depression Rating Scale (CDRS) comparison before after therapy4 weeks
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

Shalvata Mental health Center

🇮🇱

Hod Hasharon, Israel

Shalvata Mental Health Center

🇮🇱

Hod Hasharon, Israel

Shalvata Mental health Center
🇮🇱Hod Hasharon, Israel
Yuval Bloch, MD
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.